[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Tag: Cancer Drugs
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
[ad_1] Updated Dec. 26, 2023 12:33 pm ET Drug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio…
‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
[ad_1] Merck and Pfizer are the latest big pharma companies to invest in this booming area. [ad_2] Source link
Novartis Raises Earnings Guidance After Key Drugs Boost Profit, Sales
[ad_1] Updated Oct. 24, 2023 3:04 am ET Novartis raised its full-year earnings guidance for the third time this year after it reported higher net profit and sales for the…
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
[ad_1] The deal expands the pharmaceutical company’s portfolio of cancer drugs. [ad_2] Source link
Cancer Runs in Families. Too Few Are Getting Tested.
[ad_1] Doctors are recommending genetic tests to more cancer patients and their families. Costs have dropped, and the results are helping doctors choose newer targeted drugs. [ad_2] Source link
New Treatment for Bladder Cancer Offers This Biotech a Second Chance
[ad_1] UroGen hopes to have success with a new treatment after its first drug was a commercial flop. [ad_2] Source link